While there are ongoing clinical trials evaluating the efficacy of BRAF inhibitors in pediatric low grade astrocytomas, perhaps it is now worth screening all pediatric astrocytic tumors, including PXA and PGBM, for MAPK alterations in the hopes of enrolling patients with a tumor with one of these mutations in rationally designed therapeutic trials. The gene discussed is BRAF; the disease is astrocytic tumor.